论文部分内容阅读
目的:探讨c-Src在乳腺癌三苯氧胺(TAM)中耐药的表达及意义。方法:用Western blot法检测TAM治疗耐药与敏感的两种人乳腺癌MCF-7细胞中c-Src的表达及其磷酸化水平;用c-Src阻滞剂PP2处理两种细胞后,采用酶联免疫吸附试验(ELISA)及吖啶橙/溴化乙锭(AO/EB)双荧光染色法检测细胞凋亡情况。结果:与TAM敏感MCF-7细胞比较,TAM耐药MCF-7细胞c-Src的表达量及其磷酸化水平均明显增高;PP2处理后,TAM敏感MCF-7细胞的富集指数(EF)及细胞凋亡率高于TAM耐药MCF-7细胞(均P<0.05)。结论:c-Src在TAM治疗耐药的人乳腺癌MCF-7细胞株中处于高表达及高活性状态,并可能参与乳腺癌内分泌治疗耐药的机制。
Objective: To investigate the expression and significance of c-Src in breast cancer tamoxifen (TAM). Methods: Western blot was used to detect the expression and phosphorylation of c-Src in TAM-resistant and sensitive human breast cancer MCF-7 cells. After treatment of both cells with c-Src inhibitor PP2, Cell apoptosis was detected by enzyme-linked immunosorbent assay (ELISA) and acridine orange / ethidium bromide (EB / EB) double staining. Results: Compared with TAM-sensitive MCF-7 cells, the expression level of c-Src and the phosphorylation level of TAM-resistant MCF-7 cells were significantly increased. After PP2 treatment, the enrichment index (EF) And the rate of apoptosis was higher than TAM-resistant MCF-7 cells (all P <0.05). Conclusion: c-Src is highly expressed and highly active in TAM-resistant human breast cancer cell line MCF-7 and may be involved in the mechanism of endocrine-resistance in breast cancer.